← Back to Search

MCL1 inhibitor

PRT1419 for Sarcoma

Phase 1

Waitlist Available

Research Sponsored by Prelude Therapeutics

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline through approximately 2 years

Awards & highlights

Study Summary

This trial is testing a new cancer drug to see what the best dose is and how well it works.

Eligible Conditions

Sarcoma
Melanoma
Lung Cancer
Breast Cancer
Esophageal Cancer
Cervical Cancer
Head and Neck Cancers

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline through approximately 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline through approximately 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through approximately 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Dose limiting toxicities (DLT) of PRT1419

Maximally tolerated dose (MTD) and/or optimal biological dose (OBD)

Recommended phase 2 dose (RP2D) and schedule of PRT1419

Secondary outcome measures

Anti-tumor activity of PRT1419: measurement of objective responses

Pharmacokinetic profile of PRT1419: maximum observed plasma concentration

Progression-free survival

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: PRT1419Experimental Treatment1 Intervention

PRT1419 will be administered by intravenous infusion

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

PRT1419

2020

Completed Phase 1

~50

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Prelude TherapeuticsLead Sponsor

8 Previous Clinical Trials

629 Total Patients Enrolled

2 Trials studying Sarcoma

52 Patients Enrolled for Sarcoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the potential hazards associated with PRT1419 consumption?

"Data surrounding PRT1419's safety and efficacy is limited, thus it has been rated a 1 on our Power scale."

Answered by AI

Is it possible to currently enlist in this clinical experiment?

"According to clinicaltrials.gov, this medical experiment is actively recruiting participants and was originally made available on August 11th 2021 with the latest update being May 26th 2022."

Answered by AI

How many venues are hosting this clinical trial?

"This clinical trial is operating from numerous sites, including Thomas Jefferson University's Sidney Kimmel Cancer Center in Philadelphia and the Sarah Cannon Research Institute at HealthONE in Denver. Additionally, UPMC Hillman Cancer Center located in Sarasota, Colorado serves as another research location."

Answered by AI

What outcomes is this research endeavor seeking to realize?

"According to the sponsoring organisation, Prelude Therapeutics, this trial's chief goal is Dose Limiting Toxicities (DLT) of PRT1419 over a two-year period. Other assessed outcomes include Anti-tumor activity measured through objective responses, Pharmacokinetic profile with maximum observed plasma concentration and Progression-free survival until either death or criteria for disease progression are met."

Answered by AI

What is the highest amount of participants this research has enrolled?

"To ensure the success of this trial, 30 qualified individuals are needed. Thomas Jefferson University, Sidney Kimmel Cancer Center in Philadelphia and Sarah Cannon Research Institute at HealthONE in Sarasota have all been approved to conduct this study and recruit these participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of PRT1419 in Patients With Advanced Solid Tumors

2021. "A Study of PRT1419 in Patients With Advanced Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04837677.